Primary Pulmonary Lymphoepithelioma-Like Carcinoma Demonstrates a Favorable Response to Tislelizumab Combined with Chemotherapy: A Case Report  

作　　者：Qianglong Lin Xiaofen Ma Qianglong Lin;Xiaofen Ma(Department of Nuclear Medicine, The Affiliated Guangdong Second Provincial General Hospital of Jinan University, Guangzhou, China)

机构地区：[1]Department of Nuclear Medicine, The Affiliated Guangdong Second Provincial General Hospital of Jinan University, Guangzhou, China

出　　处：《Journal of Biosciences and Medicines》2025年第2期122-128,共7页生物科学与医学(英文)

摘　　要：Background: Primary pulmonary lymphoepithelioma-like carcinoma (LELC) is a rare subtype of non-small cell lung cancer (NSCLC). Nevertheless, no universally acknowledged standards of care have been reported to be effective and productive for the treatment of this tumor. Materials and Methods: A patient with advanced primary pulmonary LELC was treated by employing a combination of tislelizumab and chemotherapy. Results: The patient displayed a favorable response to the combination therapy. The tumor size exhibited conspicuous abatement in contrast to the pre-treatment baseline, and the tumor markers normalized. Conclusion: The combination of immunotherapy with chemotherapy appears to be more effective than therapy alone for managing advanced primary pulmonary LELC. On that account, further clinical trials are imperative to establish this combination regimen as a potential first-line treatment option for advanced cases.Background: Primary pulmonary lymphoepithelioma-like carcinoma (LELC) is a rare subtype of non-small cell lung cancer (NSCLC). Nevertheless, no universally acknowledged standards of care have been reported to be effective and productive for the treatment of this tumor. Materials and Methods: A patient with advanced primary pulmonary LELC was treated by employing a combination of tislelizumab and chemotherapy. Results: The patient displayed a favorable response to the combination therapy. The tumor size exhibited conspicuous abatement in contrast to the pre-treatment baseline, and the tumor markers normalized. Conclusion: The combination of immunotherapy with chemotherapy appears to be more effective than therapy alone for managing advanced primary pulmonary LELC. On that account, further clinical trials are imperative to establish this combination regimen as a potential first-line treatment option for advanced cases.

关 键 词：Primary Pulmonary Lymphoepithelioma-Like Carcinoma LELC Tislelizumab Immune Checkpoint Inhibitor 

分 类 号：R73[医药卫生—肿瘤]